The WHCC Health Investment Presentations at the World Health Care Congress Middle East welcomes early and later-stage entrepreneurs and companies who wish to present innovations to potential investors, partners, health care executives and journalists. The special session on will be held Monday, December 6, 2010, from 13:30-14:15 (1:30-2:15 p.m.)

For investors and organizations interested in watching the presentations and meeting with the presenters, we invite you to attend the session.

Cost: WHCC Health Investment Presentations only ($295 USD)

WHCC Health Investment Presentations and whole WHICC Middle East conference ($595 USD)

To register to attend, email [email protected] or call +1-781-939-2500.

Presenters include:

US Preventive Medicine uses its ground-breaking care delivery platform 'The Prevention Plan' to deliver the full prevention spectrum, helping companies and health systems reduce health risks, improve outcomes and reduce medical spend with published and peer-reviewed best-in-class outcomes. Active in the US and UK, US Preventive Medicine is currently looking at building partnerships and launching in various additional markets in Europe, the Middle East and Asia/Pacific.

Seha Card is a complete public healthcare management system, it empower people to manage their own health and medical conditions. Seha Card is innovative public healthcare systems that allow people access and manage their health account, communicate efficiently with their healthcare providers, and enrich their medical knowledge and reference to the most trustworthy medical information resource in the world. Seha Card provides the people of the GCC the ability to improve their healthy life style in a very culturally acceptable way, and provide the investors for application world-wide.|

Mobisante, Inc. is a privately held mHealth product and services company founded in 2009. Its goal is to make ultrasound imaging more affordable and accessible to help health care professionals practice better medicine and to reduce costs. Mobisante is building highly portable, affordable, and connected ultrasound systems that are based on a smart phone. Mobisante won a Best Mobile Healthcare Device award at the Mobile Health Expo in 2010 for its design.  

Glycosyn, Inc. is a biotechnology therapeutics and diagnostics company, dedicated to reducing or eliminating infant and childhood diarrhea worldwide, the primary cause of morbidity and mortality among children. In addition, Glycosyn is developing products for traveler’s diarrhea and animal health, as well as diagnostics and therapeutics targeting necrotizing enterocolitis and other conditions. Worldwide, infectious diarrhea is responsible for approximately 20 percent of all mortality in children under the age of 5, and for an estimated 2 million deaths annually. In addition to directly causing illness and death, diarrhea contributes to mortality from other diseases in children, including malnutrition and malaria. In the United States, although the overall infectious diarrhea mortality rate is lower, the disease nevertheless has an annual incidence of more than 375 million cases in pediatric and adult populations, and is responsible for approximately 900,000 hospitalizations and 6,000 deaths per year. Included in these numbers are 200,000 children under five years of age hospitalized in the U.S. each year with active diarrheal disease, accounting for nearly 880,000 inpatient days, over 500 deaths, and almost $ 1billion of in-patient cost.

Located in the heart of Europe, the UZ Brussel (Brussels University Hospital) is one of Belgium's premier Centers of Excellence in healthcare, biomedical research and medical education. The hospital is associated with the Faculty of Medicine & Pharmacy of the Free University of Brussels. As a top-rate hospital, the UZ Brussel has gained recognition at both a national and an international level. It is a 3000 staff, 300 MIO € budgeted, 450 MD&PhD hospital. With its 730 beds, close to 53,000 inpatients (hospitalizations and day clinic) and 500,000 outpatients are treated every year. Its scientific production includes 350 scientific, peer-reviewed papers per year and various spin-off companies.